Full history for every metric is available with a Kvantra account
Catalent, Inc. (CTLT)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2,518 | 3,094 | 3,998 | 4,828 | 4,276 | 4,381 | 4,422 |
| Operating profit | $m | -749 | - | |||||
| Net profit | $m | 137 | 173 | 585 | 499 | -232 | -1,043 | -413 |
| EPS reported | $ | -5.76 | -2.26 | |||||
| Operating cashflow per share | $ | 1.48 | 1.48 | |||||
| Capex per share | $ | 1.81 | 1.81 | |||||
| FCF per share | $ | -0.33 | -0.33 | |||||
| Free cash flow | $m | -59 | 99 | |||||
| Net debt | $m | 4,304 | 4,599 | |||||
| Book value equity | $m | 3,604 | 3,542 | |||||
| Book value per share | $ | 19.91 | 19.46 | |||||
| Number of shares | m | 181 | 182 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2.82 | 3.25 | |||||
| P/S LTM | x | 2.32 | 2.61 | |||||
| P/FCF LTM | x | -172.29 | 116.39 | |||||
| EV/EBITDA LTM | x | -52.34 | 40.40 | |||||
| EV/Sales LTM | x | 3.39 | 3.65 | |||||
| Earnings Yield LTM | % | -10.26% | -9.08% | |||||
| FCF Yield | % | -0.58% | 0.86% | |||||
| Quality | ||||||||
| ROE | % | -28.94% | -25.32% | |||||
| ROIC | % | -8.53% | -8.53% | |||||
| Operating margin | % | -17.10% | -17.10% | |||||
| Gross margin | % | 21.75% | 21.75% | |||||
| FCF/Sales | % | -1.35% | -1.35% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +2.46% | +4.39% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.01 | 0.02 | |||||
| Net Debt/EBITDA | x | -16.55 | -16.55 | |||||
| EBIT/Net interest | x | -2.95 | -2.95 | |||||
| Net debt/market cap | % | 42.34% | 39.91% | |||||
| Net debt/Equity | x | 1.19 | 1.30 | |||||
| Gross debt/equity | x | 1.38 | 1.40 | |||||
Company overview
Catalent, Inc., operating globally through its various subsidiaries, specializes in the development and production of comprehensive solutions for a wide array of products, including pharmaceutical drugs, protein-based biologics, advanced cell and gene therapies, and consumer health items. The company's operations are strategically divided into four key segments: Biologics; Softgel and Oral Technologies; Oral and Specialty Delivery; and Clinical Supply Services. The Softgel and Oral Technologies division focuses on the formulation, development, and manufacturing of soft capsules. These are utilized in a diverse range of client products, such as prescription medications, over-the-counter drugs, nutritional supplements, unit-dose cosmetics, and medicinal preparations for animal health. Within the Biologics segment, Catalent undertakes the creation of biologic cell lines, develops and manufactures both cell therapy and viral-based gene therapy, and handles the formulation and production of parenteral dose forms, including vials, prefilled syringes, and cartridges. This segment also provides essential analytical development and testing capabilities. The Oral and Specialty Delivery segment offers extensive formulation, development, and manufacturing expertise across various technologies. It provides integrated downstream solutions spanning clinical development and commercial supply. This segment also features a dedicated oral delivery solutions platform, encompassing preclinical screening, formulation, analytical development, and current good manufacturing practices (cGMP) services. Finally, the Clinical Supply Services segment delivers vital support for drug and biologic clinical trials. Its services include manufacturing, specialized packaging, secure storage, efficient distribution, and comprehensive inventory management. This segment also offers "FastChain," a demand-led clinical supply service. Catalent serves a broad client base, including pharmaceutical, biotechnology, and consumer health organizations, alongside companies in other healthcare sectors like animal health and medical devices, and even the cosmetics industry. The company was founded in 2007 and maintains its headquarters in Somerset, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Catalent, Inc. (CTLT)
Catalent, Inc., operating globally through its various subsidiaries, specializes in the development and production of comprehensive solutions for a wide array of products, including pharmaceutical drugs, protein-based biologics, advanced cell and gene therapies, and consumer health items. The company's operations are strategically divided into four key segments: Biologics; Softgel and Oral Technologies; Oral and Specialty Delivery; and Clinical Supply Services. The Softgel and Oral Technologies division focuses on the formulation, development, and manufacturing of soft capsules. These are utilized in a diverse range of client products, such as prescription medications, over-the-counter drugs, nutritional supplements, unit-dose cosmetics, and medicinal preparations for animal health. Within the Biologics segment, Catalent undertakes the creation of biologic cell lines, develops and manufactures both cell therapy and viral-based gene therapy, and handles the formulation and production of parenteral dose forms, including vials, prefilled syringes, and cartridges. This segment also provides essential analytical development and testing capabilities. The Oral and Specialty Delivery segment offers extensive formulation, development, and manufacturing expertise across various technologies. It provides integrated downstream solutions spanning clinical development and commercial supply. This segment also features a dedicated oral delivery solutions platform, encompassing preclinical screening, formulation, analytical development, and current good manufacturing practices (cGMP) services. Finally, the Clinical Supply Services segment delivers vital support for drug and biologic clinical trials. Its services include manufacturing, specialized packaging, secure storage, efficient distribution, and comprehensive inventory management. This segment also offers "FastChain," a demand-led clinical supply service. Catalent serves a broad client base, including pharmaceutical, biotechnology, and consumer health organizations, alongside companies in other healthcare sectors like animal health and medical devices, and even the cosmetics industry. The company was founded in 2007 and maintains its headquarters in Somerset, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free